International Journal of Antimicrobial Agents
Volume 32, Issue 2 , Pages 145-153 , August 2008

Oral levofloxacin 500mg once daily in the treatment of chronic bacterial prostatitis

  • K.G. Naber

      Affiliations

    • Technical University of Munich, Munich, Germany
    • Corresponding Author InformationCorresponding author. Present address: Karl-Bickleder-Str. 44c, D-94315 Straubing, Germany. Tel.: +49 9421 33369.
    • ,
  • K. Roscher

      Affiliations

    • Medical Affairs, Sanofi-Aventis Deutschland GmbH, Potsdamer Str. 8, 10785 Berlin, Germany
    • ,
  • H. Botto

      Affiliations

    • Hôpital Foch, 40 rue Worth, BP 36, 92151 Suresnes, France
    • ,
  • V. Schaefer

      Affiliations

    • Institute of Medical Microbiology, University of Frankfurt, Paul-Ehrlich-Str. 40, 60596 Frankfurt, Germany

Received 10 November 2007 ,Accepted 25 March 2008.

References 

  1. Roehrborn C The MTOPS Research Group. The impact of acute or chronic inflammation in baseline biopsy on the risk of progression in the MTOPS study. Eur Urol. 2005;3:5
  2. Krieger JN, Nyberg L, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA. 1999;282:236–237
  3. Krieger JN, Morganstern SL, Nickel JC. Diagnosing prostatitis: a clinical dilemma. Patient Care. Summer 1998;1–20
  4. Meares EM, Stamey TA. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol. 1968;5:492–518
  5. Meares EM, Stamey TA. Bacterial prostatitis and recurrent urinary tract infections. In:  Hoeprich PD editors. Infectious diseases. 1st ed.. Hagerstown, MD: Harper & Row; 1972;p. 467–473
  6. Nickel JC. The pre and post massage test (PPMT): a simple screen for prostatitis. Techniques Urol. 1997;3:38–43
  7. Nickel JC, Shoskes D, Wang Y, Alexander RB, Fowler JE, Zeitlin S, et al. How does the pre-massage and post-massage 2-glass test compare to the Meares-Stamey 4-glass test in men with chronic prostatitis/chronic pelvic pain syndrome?. J Urol. 2006;176:119–124
  8. Naber KG, Boerema JBJ, Bischoff W, Blenk H, Focht J, Carpentier P, et al. An assessment of temafloxacin in the treatment of chronic bacterial prostatitis. J Antimicrob Chemother. 1991;28:87–96
  9. Cox CE, Childs SJ. Treatment of chronic bacterial prostatitis with temafloxacin. Am J Med. 1991;91:134S–139S
  10. Naber KG, Busch W, Focht J The German Prostatitis Study Group. Ciprofloxacin in the treatment of chronic bacterial prostatitis: a prospective, non-comparative multicentre clinical trial with long-term follow-up. Int J Antimicrob Agents. 2000;14:143–149
  11. Naber KG The European Lomefloxacin Prostatitis Study Group. Lomefloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis. Int J Antimicrob Agents. 2002;20:18–27
  12. Bundrick W, Heron SP, Ray P, Schiff WM, Tenennberg AM, Wiesinger BA, et al. Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. Urology. 2003;62:537–541
  13. Drach GW. Trimethoprim sulfamethoxazole therapy of chronic bacterial prostatitis. J Urol. 1974;111:637–639
  14. Giamarellou H, Kosmidis J, Leonidas M, Papadakis M, Daikos GK. A study of the effectiveness of rifaprim in chronic prostatitis caused mainly by Staphylococcus aureus. J Urol. 1982;128:321–324
  15. Nickel JC, Costerton JW. Coagulase-negative staphylococcus in chronic prostatitis. J Urol. 1992;147:398–400
  16. Tanner MA, Shoskes D, Shahed A, Pace NR. Prevalence of corynebacterial 16S rRNA sequences in patients with bacterial and ‘nonbacterial’ prostatitis. J Clin Microbiol. 1999;37:1863–1870
  17. Krieger JN, Ross SO, Limaye AP, Riley DE. Inconsistent localization of gram-positive bacteria to prostate-specific specimens from patients with chronic prostatitis. Urology. 2005;66:721–725
  18. Kamidono S, Arakawa S, Ishigami J, Sasai S, Kumamoto Y, Kawamura N, et al. Proposal of a standard method for clinical evaluation of antimicrobial agents in prostatitis. Specification of patients and criteria for evaluation of clinical efficacy. Acta Urol Jpn. 1989;35:427–445
  19. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 7th ed. Approved standard M7-A7. Wayne, PA: CLSI; 2006.
  20. Wagenlehner FME, Weidner W, Naber KG. Therapy for prostatitis, with emphasis on bacterial prostatitis. Expert Opin Pharmacother. 2007;8:1–8
  21. Wagenlehner FM, Kinzig-Schippers M, Sörgel F, Weidner W, Naber KG. Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose. Int J Antimicrob Agents. 2006;28:551–559
  22. Wagenlehner FM, Kinzig-Schippers M, Tischmeyer U, Wagenlehner C, Sörgel F, Naber KG. Urinary bactericidal activity of extended-release ciprofloxacin (1 000 milligrams) versus levofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. Antimicrob Agents Chemother. 2006;50:3947–3949
  23. Drusano GL, Preston SL, Van Guilder M, North D, Gombert M, Oefelein M, et al. A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin. Antimicrob Agents Chemother. 2000;44:2046–2051
  24. Bulitta J, Kinzig M, Naber CK, Naber KG, Sauber C, Kleinschnitz M, et al. Limitations in the use of drug cocktails (DC) to compare the pharmacokinetics (PK) of drugs: ciprofloxacin (CIP) vs. levofloxacin (LEV). In: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 17-20 September 2000; Toronto, Canada. 2000;Abstract 506
  25. Nickel JC, Olson ME, Costerton JW. Rat model of experimental bacterial prostatitis. Infection. 1991;19:S126–S130

PII: S0924-8579(08)00148-9

doi: 10.1016/j.ijantimicag.2008.03.014

International Journal of Antimicrobial Agents
Volume 32, Issue 2 , Pages 145-153 , August 2008

Article Tools

* Image Usage & Resolution